Aflac (NYSE:AFL – Get Free Report) is expected to be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $1.77 per share and revenue of $4.3577 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.
Aflac (NYSE:AFL – Get Free Report) last issued its earnings results on Monday, February 27th. The financial services provider reported $1.07 earnings per share for the quarter. The company had revenue of $5.91 billion for the quarter. Aflac had a return on equity of 15.08% and a net margin of 15.32%. On average, analysts expect Aflac to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Aflac Stock Performance
AFL stock opened at $107.19 on Friday. The firm has a 50 day simple moving average of $108.61 and a 200 day simple moving average of $105.60. Aflac has a 52 week low of $96.95 and a 52 week high of $115.43. The stock has a market cap of $57.33 billion, a P/E ratio of 24.31, a P/E/G ratio of 2.93 and a beta of 0.86. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.11 and a current ratio of 0.11.
Aflac Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Wednesday, August 20th were paid a dividend of $0.58 per share. The ex-dividend date of this dividend was Wednesday, August 20th. This represents a $2.32 dividend on an annualized basis and a dividend yield of 2.2%. Aflac’s dividend payout ratio (DPR) is 52.61%.
Insider Activity at Aflac
In other news, Director Joseph L. Moskowitz sold 1,000 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $102.57, for a total value of $102,570.00. Following the completion of the sale, the director directly owned 25,105 shares in the company, valued at approximately $2,575,019.85. The trade was a 3.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. boosted its holdings in Aflac by 7.6% during the second quarter. Raymond James Financial Inc. now owns 1,568,841 shares of the financial services provider’s stock valued at $165,450,000 after acquiring an additional 110,978 shares during the period. Captrust Financial Advisors lifted its position in shares of Aflac by 2.5% during the 2nd quarter. Captrust Financial Advisors now owns 1,156,864 shares of the financial services provider’s stock worth $122,003,000 after purchasing an additional 28,158 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in Aflac by 12.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 494,511 shares of the financial services provider’s stock valued at $52,151,000 after purchasing an additional 55,843 shares during the period. Quantinno Capital Management LP grew its holdings in Aflac by 5.2% in the 2nd quarter. Quantinno Capital Management LP now owns 228,941 shares of the financial services provider’s stock valued at $24,144,000 after buying an additional 11,298 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Aflac by 167.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 205,674 shares of the financial services provider’s stock worth $21,690,000 after buying an additional 128,900 shares during the period. Institutional investors and hedge funds own 67.44% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Evercore ISI set a $110.00 price target on shares of Aflac and gave the stock an “underperform” rating in a research note on Thursday, October 9th. Keefe, Bruyette & Woods upped their target price on Aflac from $108.00 to $110.00 and gave the stock a “market perform” rating in a research report on Thursday, October 9th. Wall Street Zen raised Aflac from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Wells Fargo & Company lifted their price target on Aflac from $105.00 to $107.00 and gave the company an “equal weight” rating in a report on Monday, August 11th. Finally, Piper Sandler set a $125.00 price objective on Aflac and gave the stock an “overweight” rating in a report on Tuesday, October 7th. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Aflac presently has a consensus rating of “Hold” and an average price target of $109.90.
Check Out Our Latest Research Report on Aflac
Aflac Company Profile
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Further Reading
- Five stocks we like better than Aflac
- What is a support level?
- Is Beyond Meat a Buy After Meme Stock Surge? Analysts Say No
- Which Wall Street Analysts are the Most Accurate?
- ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
- Consumer Staples Stocks, Explained
- Super Micro’s Moment of Truth: A Growth Story Under Pressure
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.
